EMD people will wish they bought at 10c. EMD seeks 2021 registration for EMD-003, a cannabinoid-based medicine to reduce symptoms of anxiety, depression and stress. Doing 3 clinical trials this year.
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint
